(NewsDirect)
Emergent HealthCorp. (OTC: EMGE) , a curator, developer, and marketer ofproducts in the Regenerative Health Space announced revenues of$340,531 for the quarter ended March 31, 2023, as compared to $14,267for the quarter ended March 31, 2022, an increase of over 2300%. The financial statement can be viewed in its entirety at https://www.otcmarkets.com/stock/EMGE/disclosure .
Jim Morrison, formerL'Oréal President and Emergent’s full time CEO stated "Q1was a good starting point for the 'new look' EMGE. You willsee the effect of many of our new business initiatives as we move intothe second quarter and throughout the year. We are on track for 2023to be a very good year."
Emergent believes it will continue increasing itsrevenues quarter over quarter as it expands its business internallyand externally through acquisition.
Recent Developments:
On May 11, 2023, announced that itssubsidiary EvolutionaryBiologics, Inc. (EvoBio), a developer, manufacturer anddistributor of private label regenerative medicine products andbranded state-of-the-art biologic products, created in apharmaceutical grade laboratory and manufacturing facility hasexecuted a Product Manufacturing Agreement with a distributor ofmedical devices that desires to market a MSC Exosome product fromEvoBio as a private label on an exclusive basis. The Company believesthe new relationship will generate at least $2 million in new revenue.The press release can be viewed in its entirety here .
On May 9, 2023,announced that it has engaged BFBorgers CPA PC , a full-service audit, tax, accounting, andadvisory firm, as its Public Company Accounting Oversight Board(PCAOB) qualified auditor to audit the Company’s financial statementfor the two-year period ending December 31 st , 2022according to Generally Accepted Accounting Principles (GAAP). GAAP isthe accounting standard adopted by the Securities and ExchangeCommission (SEC) and is the default accounting standard used bycompanies based in the United States. The press release can be viewedin its entirety here .
On May 4, 2023,announced the execution of an Engagement Letter with Boustead Securities LLC. toact as exclusive financial advisor with respect to a planned corporatefinancing transaction including the private placement of securities(pre-IPO Financing) and a planned $10 million initial public offeringof Emergent subsidiary PharmaZu common stock (IPO) thatwill apply for listing on NASDAQ with NO DILUTION to the EmergentShareholders. PharmaZu is a pure play, e-commerce products and serviceprovider focused on the Pet Community, Pet Pharmacy and Pet Wellnessusing Influencers and their content, including pet pharmacy, vettelehealth and pet wellness businesses. Upon the effectiveness of theIPO and listing on NASDAQ, PharmaZu plans to acquire a 49-stateauthorized compounding pharmacy located in West Palm Beach, FL, doingapproximately $10M a year in revenue, which will serve as the backboneand fulfilment center for PharmaZu, creating a national platformthroughout the United States. The raise of capital will be used forexpanding PharmaZu’s business, product offerings, as well as foracquisitions. Subsequently, Emergent plans to distribute the shares ofPharmaZu as a dividend to its shareholders, pro rata at NO COST to theEmergent Shareholders. The press release can be viewed in its entirety here .
The global biologicsmarket size was valued at US $366.43 billion in 2021 and it isexpected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGRof 7.8% from 2022 to 2030. A biologic medication is a product that ismade from live organisms and contains living organism components.Recombinant protein, tissues, allergens, genes, cells, bloodcomponents, blood, and vaccinations are all examples of biologics.Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoidarthritis, inflammatory bowel disease, and other disorders andinfections are treated with biologics. Various government efforts,higher share of biologics in the market, and rising use ofbiopharmaceuticals over chemically produced molecules, and many otherfactors are driving the biologics market expansion in the forecastperiod.
ABOUTEMERGENT HEALTH CORPORATION
Emergent curates, develops and sells products inthe Regenerative Health Space. Its products comprise of ingestibles aswell as topicals for the whole family. The company distributes itsproducts online and through Content Based Shopping using Influencersto position products in their produced content throughout the UnitedStates and Internationally. Its subsidiaries; PharmaZu , is a pure play,e-commerce products and service provider focused on the Pet Community,Pet Pharmacy and Pet Wellness using Influencers and their content,including the pet pharmacy, vet telehealth and pet wellnessbusinesses; Regen BioWellness, is a distributor of various products inthe plant-based and regenerative medical fields. Evolutionary Biologics ,is a new kind of biologics company founded for a clear purpose: bringcutting edge regenerative products to the medical community. Emergentdoes not claim any of its products are approved by the FDA todiagnose, treat, cure or prevent any disease. For more information,please visit Emergent's Website and Social Mediaon .
Before using anyproducts, you should always consult with your Veterinarian and/orFamily Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-lookingstatements that can be identified by terminology such as“believes,” “expects,” “potential,” “plans,”“suggests,” “may,” “should,” “could,” “intends,”or similar expressions. Many forward-looking statements involve knownand unknown risks, uncertainties and other factors that may causeactual results to be materially different from any future resultsimplied by such statements. These factors include, but are not limitedto, our ability to continue to enhance our products and systems toaddress industry changes, our ability to expand our customer base andretain existing customers, our ability to effectively compete in ourmarket segment, the lack of public information on our company, ourability to raise sufficient capital to fund our business, operations,our ability to continue as a going concern, and a limited publicmarket for our common stock, among other risks. Many factors aredifficult to predict accurately and are generally beyond thecompany's control. Forward-looking statements speak only as to thedate they are made, and we do not undertake to update forward-lookingstatements to reflect circumstances or events that occur after thedate the forward-looking statements are made.
FOR MORE INFORMATION,PLEASE CONTACT:
Jim Morrison, CEO
Emergent HealthCorporation Website
i nfo@emergenthealthcompany.com
ContactDetails
Emergent Health Corp.
info@emergenthealthcompany.com
CompanyWebsite
https://emergenthealthcompany.com/
Copyright (c) 2023 TheNewswire - All rights reserved.